BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32608081)

  • 21. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways.
    Xu H; Jia Y; Li J; Huang X; Jiang L; Xiang T; Xie Y; Yang X; Liu T; Xiang Z; Sheng J
    Biomed Pharmacother; 2022 May; 149():112902. PubMed ID: 35364377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Geraniin suppresses RANKL-induced osteoclastogenesis in vitro and ameliorates wear particle-induced osteolysis in mouse model.
    Xiao F; Zhai Z; Jiang C; Liu X; Li H; Qu X; Ouyang Z; Fan Q; Tang T; Qin A; Gu D
    Exp Cell Res; 2015 Jan; 330(1):91-101. PubMed ID: 25016282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanthanum Chloride Attenuates Osteoclast Formation and Function Via the Downregulation of Rankl-Induced Nf-κb and Nfatc1 Activities.
    Jiang C; Shang J; Li Z; Qin A; Ouyang Z; Qu X; Li H; Tian B; Wang W; Wu C; Wang J; Dai M
    J Cell Physiol; 2016 Jan; 231(1):142-51. PubMed ID: 26060084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Artesunate suppresses RANKL-induced osteoclastogenesis through inhibition of PLCγ1-Ca
    Zeng X; Zhang Y; Wang S; Wang K; Tao L; Zou M; Chen N; Xu J; Liu S; Li X
    Biochem Pharmacol; 2017 Jan; 124():57-68. PubMed ID: 27789216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LDC000067 suppresses RANKL-induced osteoclastogenesis in vitro and prevents LPS-induced osteolysis in vivo.
    Xue S; Shao Q; Zhu LB; Jiang YF; Wang C; Xue B; Lu HM; Sang WL; Ma JZ
    Int Immunopharmacol; 2019 Oct; 75():105826. PubMed ID: 31437791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protocatechualdehyde inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclastogenesis and attenuates lipopolysaccharide-induced inflammatory osteolysis.
    Huang H; Jiang W; Hong K; Cai J; He Y; Ma X; Wu P; Lang J; Ma Y; Huang C; Yuan J
    Phytother Res; 2021 Jul; 35(7):3821-3835. PubMed ID: 33778997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Garcinol suppresses RANKL-induced osteoclastogenesis and its underlying mechanism.
    Jia Y; Jiang J; Lu X; Zhang T; Zhao K; Han W; Yang W; Qian Y
    J Cell Physiol; 2019 May; 234(5):7498-7509. PubMed ID: 30471112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protein kinase C inhibitor, GF109203X attenuates osteoclastogenesis, bone resorption and RANKL-induced NF-κB and NFAT activity.
    Yao J; Li J; Zhou L; Cheng J; Chim SM; Zhang G; Quinn JM; Tickner J; Zhao J; Xu J
    J Cell Physiol; 2015 Jun; 230(6):1235-42. PubMed ID: 25363829
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynein light chain LC8 inhibits osteoclast differentiation and prevents bone loss in mice.
    Kim H; Hyeon S; Kim H; Yang Y; Huh JY; Park DR; Lee H; Seo DH; Kim HS; Lee SY; Jeong W
    J Immunol; 2013 Feb; 190(3):1312-8. PubMed ID: 23293355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
    Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
    Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1.
    Yamashita T; Yao Z; Li F; Zhang Q; Badell IR; Schwarz EM; Takeshita S; Wagner EF; Noda M; Matsuo K; Xing L; Boyce BF
    J Biol Chem; 2007 Jun; 282(25):18245-18253. PubMed ID: 17485464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artesunate inhibits RANKL-induced osteoclastogenesis and bone resorption in vitro and prevents LPS-induced bone loss in vivo.
    Wei CM; Liu Q; Song FM; Lin XX; Su YJ; Xu J; Huang L; Zong SH; Zhao JM
    J Cell Physiol; 2018 Jan; 233(1):476-485. PubMed ID: 28294321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
    Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
    Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades.
    Song F; Wei C; Zhou L; Qin A; Yang M; Tickner J; Huang Y; Zhao J; Xu J
    J Cell Physiol; 2018 Feb; 233(2):1723-1735. PubMed ID: 28681916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hesperetin suppresses RANKL-induced osteoclastogenesis and ameliorates lipopolysaccharide-induced bone loss.
    Liu H; Dong Y; Gao Y; Zhao L; Cai C; Qi D; Zhu M; Zhao L; Liu C; Guo F; Xiao J; Huang H
    J Cell Physiol; 2019 Jul; 234(7):11009-11022. PubMed ID: 30548260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.